

Key Opportunities and Challenges for the Future of Cancer Treatment
Monday, January 8, 2018
8am -11:30am
Agenda

8:00	Welcome & Introductions	Rick Klausner, MD
8:05	Overview of Friends of Cancer Research Collaborations & Policy Initiatives	Ellen Sigal, PhD Jeff Allen, PhD
8:15	Past & Future of Drug Development	Rick Pazdur, MD
8:35	Emerging Priorities Targeted Therapies PD-1/PD-L1 Therapies Bioinformatics Biologics & Gene Therapies	Gideon Blumenthal, MD Marc Theoret, MD Sean Khozin, MD Ke Liu, MD, PhD
8:50	The View from CMS How CMS makes decisions in terms of process A summary of recent CMS activity relevant to cancer CMS' interest in new ideas and requests for information	Demetrios Kouzoukas, JD Anand Shah, MD, MPH

Program & Discussion: Unprecedented Opportunities/Unprecedented Challenges

9:15	Breaking Barriers to cancer immunotherapy discoveries The Parker Institute for Cancer Immunotherapy Model	Jeff Bluestone, PhD
9:35	Cell Based Therapy in Oncology – special issues	Hans Bishop
9:55	Panel Discussion: Flooding the System <i>(moderated by Rick Klausner, MD)</i> Topics: The many challenges with reverse translation Too many choices Too many tests	With comments by: Mathai Mammen MD PhD Terry Rosen, PhD Jennifer Wargo, MD
10:40	Panel Discussion – Future Opportunities in Clinical Trials <i>(moderated by George Demetri, MD)</i> Topics: Phase 0 Trials IO trials infrastructure Novel trial designs	With comments by: Stan Riddell, MD Dan Auclair, PhD George Demetri, MD
11:20	Closing thoughts	Rick Pazdur, MD, Anand Shah, MD, Demetrios Kouzoukas, JD, and Rick Klausner, MD
11:40	Adjourn	